Search hospitals > Connecticut > Bridgeport

Bridgeport Hospital

Claim this profile
Bridgeport, Connecticut 06610
Global Leader in Cardiovascular Disease
Global Leader in Breast Cancer
Conducts research for Heart Attack
Conducts research for Stroke
Conducts research for Heart Failure
92 reported clinical trials
6 medical researchers
Photo of Bridgeport Hospital in BridgeportPhoto of Bridgeport Hospital in BridgeportPhoto of Bridgeport Hospital in Bridgeport

Summary

Bridgeport Hospital is a medical facility located in Bridgeport, Connecticut. This center is recognized for care of Cardiovascular Disease, Breast Cancer, Heart Attack, Stroke, Heart Failure and other specialties. Bridgeport Hospital is involved with conducting 92 clinical trials across 136 conditions. There are 6 research doctors associated with this hospital, such as Adam Schussheim, Edward Tuohy, MD, Alisa Savetamal, MD, and Caroline Loeser, MD.

Area of expertise

1Cardiovascular Disease
Global Leader
Bridgeport Hospital has run 14 trials for Cardiovascular Disease.
2Breast Cancer
Global Leader
Bridgeport Hospital has run 12 trials for Breast Cancer. Some of their research focus areas include:
PR positive
ER positive
HER2 negative

Top PIs

Clinical Trials running at Bridgeport Hospital

Heart Failure
Cardiovascular Disease
Sleep Apnea
Stroke
Type 2 Diabetes
Pelvic Organ Prolapse
High Blood Pressure
Atherosclerosis
Elevated Lipoprotein
Obstructive Sleep Apnea Syndrome
Image of trial facility.

BI 690517 + Empagliflozin

for Heart Failure

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.
Recruiting1 award Phase 32 criteria
Image of trial facility.

Vicadrostat + Empagliflozin

for Heart Failure

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before the study. The purpose of this study is to find out whether a medicine called vicadrostat, in combination with another medicine called empagliflozin, helps people with chronic heart failure. In this study, participants are put into 2 groups randomly. Participants have an equal chance of being in either group. One group takes vicadrostat/empagliflozin tablets, and the other group takes placebo/empagliflozin tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take the study medicines as tablets once a day for between 1 and about 3.5 years. During this time, they can continue their regular treatment for heart failure. Participants can stay in the study as long as they benefit from treatment and can tolerate it, for a maximum of about 3.5 years. During this time, they visit the study site regularly. The exact number of visits is different for each participant, depending on how long they stay in the study. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The doctors document when participants experience worsening of their heart failure symptoms, must go to hospital due to heart failure, or die during the study. The time until these events are observed is compared between the treatment groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Recruiting1 award Phase 31 criteria
Image of trial facility.

Ziltivekimab

for Heart Failure

This trial is testing ziltivekimab to see if it can help people with heart failure and inflammation by reducing inflammation and improving heart function.
Recruiting1 award Phase 37 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Bridgeport Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security